The concept of innovative drugs is strengthening, and the ChinaAMC CSI 500 ETF (512500) is steadily rising in the afternoon at a high level

The ChinaAMC CSI 500 ETF (512500) rose steadily in the afternoon, with the latest price at 4.313 yuan, an increase of 1.173%. The constituent stocks of the CSI 500 Index tracked by this ETF are active, with several small and mid-cap growth stocks rebounding. The liquidity is good, with a transaction volume reaching 204 million yuan. The innovative drug concept is gaining strength, with catalytic factors including over 60 billion USD in external licensing for innovative drugs in the first quarter, marking a harvest period for the industry. Changcheng Guorui Securities pointed out that the catalytic factors in the pharmaceutical and biotechnology sector continue to accumulate, with policy support and active overseas cooperation driving the valuation recovery of small and mid-cap stocks